Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB

Malaisamy, Muniyandi and Nagarajan, Karikalan and Chelvanayagam, Karthick and Rajsekar, Kavitha and Tyagi, Kirti and Chandrasekaran, Padmapriyadarsini (2025) Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB. Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care bedaquiline containing regimen for MDR/RR-TB, 162(5) (581591).

Text 202545.pdf - Published Version Download (412kB)

Abstract

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquiline, pretomanid, linezolid (BPaL) and BPaL with moxifloxacin (BPaLM). We conducted an economic evaluation to assess whether the introduction of BPaL/BPaLM regimen under National Tuberculosis Elimination Programme (NTEP) for the treatment of multi-drug resistant (MDR)/RR-TB is a cost-effective strategy. The idea was to estimate the incremental cost incurred from BPaL/BPaLM regimen in comparison with the current mix of standard of care (SoC) regimen

Affiliation:	ICMR- National Institute for Research in Tuberculosis
Item Type:	Article
URI:	http://eprints.nirt.res.in/id/eprint/2090

Actions (login required)

View Item